ClinicalTrials.gg
CompletedNCT06828874Updated Feb 18, 2025

A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria

A Phase 4 interventional study of Levornidazole Disodium Phosphate for Injection and Ornidazole and Sodium Chloride Injection in Intraabdominal Infections, sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd. Completed at 32 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled May 2023, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
696
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Intraabdominal Infections with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Intraabdominal Infections · China.

Enrollment
2nd of 17
696 · median 268
Started
2023
with 3 others
Phase 4
5 of 22
1 open now
Registered
19th of 22
by date

Among the 22 studies in Intraabdominal Infections with a site in China, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 4, and was the 19th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

6 of the 22 studies in Intraabdominal Infections with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Intraabdominal Infections with a site in China, or all of them as a file.
02

Study summary

Anaerobic infections are very common in clinical practice. Poor control of anaerobic infections in patients undergoing abdominal surgery may lead to the occurrence of complications. The aim of this study is to explore the efficacy and safety of Levornidazole Phosphate Disodium for Injection in the treatment of patients with postoperative intra-abdominal infections caused by anaerobic bacteria.

03

Conditions studied

  • Intraabdominal Infections
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all of the following criteria may be enrolled in the study:

  1. Age between 18 and 75 years old
  2. Requires minimally invasive surgery (laparoscopic surgery or robotic-assisted surgery), open or percutaneous drainage surgery; Intra-abdominal infection caused by anaerobic bacteria as judged by the investigator, including purulent appendicitis, gangrene perforated appendicitis, periappendiceal abscess, gastric or duodenal perforation or rupture, jejunum, ileum, colorectal perforation or rupture, acute biliary tract infection and liver abscess; and meet at least one of the following two criteria: (1)At least two of the following four conditions must be met within 24 hours before surgery: abdominal pain, tenderness and fever (axillary temperature ≥ 37.5℃); white blood cell count ≥ 10×10\^9/L; C-reactive protein above the ; procalcitonin (PCT)above the upper limit of normal;(2) Computed Tomography (CT) or ultrasound confirms the presence of intra-abdominal infection
  3. Agree or plan to use the drug for the first time within 24 hours postoperatively
  4. The subjects voluntarily underwent the test and signed the form, and the process of signing the informed consent form was in line with Good Clinical Practice (GCP) guidelines

Exclusion criteria

Exclusion criteria:

Subjects who meet any of the following criteria should be excluded from this study:

  1. Those with known or suspected allergies to nitroimidazoles
  2. Patients who have participated in other studies and used drugs of other studies within 3 months prior to screening
  3. Patients who are taking other medications or have other diseases that may interfere with the evaluation of the safety or effectiveness of the drug; Or patients who are at risk of serious drug interactions due to concomitant medications(such as warfarin, as well as medications with compatibility to levornidazole, including furbencillin sodium, nafcillin sodium, omeprazole, vorbizole, potassium sodium dehydroandrographolide succinate for injection, azlocillin sodium, etc.)
  4. patients who have poor compliance and cannot complete the expected course of treatment and follow-up in the opinion of the investigator
  5. Abnormal liver function ( (ALT) or aspartate aminotransferase (AST) > 1.5 times the value; for patients with acute biliary tract infection or combined liver abscess, it can be relaxed to > 3 times the upper limit of the normal value); or abnormal kidney function ( rate ≤ 60 mL/min/1.73 m² [Cockcroft - Gault formula])
  6. Patients with serious primary diseases of important organs and systems such as cardiovascular, nervous system, endocrine system, hematopoietic system (such as heart failure, leukemia, uncontrolled diabetes, etc.), or those with malignant tumors
  7. Women during pregnancy or lactation, or women of childbearing age with a positive pregnancy test result before the trial
  8. Women of childbearing age and men who cannot take effective measures during the trial period. The time limit is from the signing of the form to 3 months after the last dose
  9. Patients with infections other than the abdomen (chronic infections that do not affect the evaluation of intra-abdominal infections [such as chronic rhinitis, chronic pharyngitis, etc.] can be included in this study)
  10. Patients with multiple organ failure
  11. Those who are considered by the investigator to be severely ill and need to be treated with other broad-spectrum antibiotics with anti-anaerobic effects (except for first/second/third generation cephalosporins, aztreonam, quinolones, aminoglycosides).
  12. Those who have received antibiotic treatment within 48 hours before enrollment and randomization(except for single dose)
  13. Those with positive test results for surface antigen, acquired immunodeficiency syndrome (AIDS) antibody, treponema pallidum antibody, and antibody
  14. Patients with lesions of the brain and spinal cord, epilepsy, organ sclerosis, hematopoietic insufficiency, chronic alcoholism
  15. Other patients who are not suitable to participate in this clinical study in the opinion of the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
696 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Drug: Levornidazole Disodium Phosphate for Injection

  • Active comparator
    Control Group

    Drug: Ornidazole and Sodium Chloride Injection

Interventions

  • DrugLevornidazole Disodium Phosphate for Injection

    1g,once daily, intravenously guttae for 4 to 7 days

  • DrugOrnidazole and Sodium Chloride Injection

    Drug pages: Ornidazole · Sodium Chloride

    0.5g at a time , 2 times per day, intravenously guttae for 4 to 7 days

06

What researchers measure

Primary outcomes

  1. Proportion of participants with clinical cure at Test of Cure (TOC) visit

    Clinical cure was defined as complete resolution of all symptoms and signs, including the return to normal of non - microbiological indicators such as preoperative imaging and laboratory tests. Symptoms and laboratory tests returned to normal using the following criteria: resolution or improvement of abdominal pain; Body temperature ≤ 37.5°C and white blood cell count \< 10×10\^9/L. persistent or incomplete resolution or worsening of symptoms and signs; or the development of new symptoms or signs and/or the use of other antimicrobial drugs against anaerobes was defined as clinically failure. The percentage of participants with clinical cure or clinical failure at TOC was summarized.

    Time frame: 5 to 10 days post-therapy

Secondary outcomes

  1. Proportion of participants with clinical cure at End of Therapy (EOT) visit

    Clinical cure was defined as complete resolution of all symptoms and signs, including the return to normal of non - microbiological indicators such as preoperative imaging and laboratory tests. Symptoms and laboratory tests returned to normal using the following criteria: resolution or improvement of abdominal pain; Body temperature ≤ 37.5°C and white blood cell count \< 10×10\^9/L.

    Time frame: Up to approximately Day 8

  2. Bacteriological efficacy at EOT visit

    Bacteriological efficacy included eradication (absence of the baseline bacterial pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a participant who is assessed as a clinical cure). Bacteriological efficacy was evaluated only in cases where anaerobic cultures were positive for specimens obtained during baseline surgery. The percentage of participants with a favorable per-participant microbiological response of eradication or presumed eradication was reported for the EOT visit.

    Time frame: Up to approximately Day 8

  3. Comprehensive efficacy at EOT visit

    Comprehensive efficacy was evaluated only in cases where anaerobic cultures were positive for specimens obtained during baseline surgery. It was an evaluation based on a combination of clinical and bacteriological results, and was divided into cured and ineffective. The former implied clinical cure with bacteria eradication or presumed eradication. The latter referred to clinical failure or bacterial non-eradication or presumed non-eradication, or both. The percentage of participants who were cured or ineffective was summarized for the EOT visit.

    Time frame: Up to approximately Day 8

  4. Bacteriological efficacy at TOC visit

    Bacteriological efficacy included eradication (absence of the baseline bacterial pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a participant who is assessed as a clinical cure). Bacteriological efficacy was evaluated only in cases where anaerobic cultures were positive for specimens obtained during baseline surgery. The percentage of participants with a favorable per-participant microbiological response of eradication or presumed eradication was reported for the TOC visit.

    Time frame: 5 to 10 days post-therapy

  5. Comprehensive efficacy at TOC visit

    Comprehensive efficacy was evaluated only in cases where anaerobic cultures were positive for specimens obtained during baseline surgery. It was an evaluation based on a combination of clinical and bacteriological results, and was divided into cured and ineffective. The former implied clinical cure with bacteria eradication or presumed eradication. The latter referred to clinical failure or bacterial non-eradication or presumed non-eradication, or both. The percentage of participants who were cured or ineffective was summarized for the TOC visit.

    Time frame: 5 to 10 days post-therapy

  6. Incidence of phlebitis during treatment

    Phlebitis may be associated with intravenous infusion of highly irritating, high-concentration drugs, or prolonged use, and is one of the safety indicators. The percentage of participants who developed phlebitis was summarized during treatment.

    Time frame: Up to approximately Day 7

  7. Percentage of participants who experienced Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The percentage of participants who experienced AEs were summarized.

    Time frame: Up to Day 10 post-therapy

07

Study locations

32 sites
  • Chizhou People's Hospital
    Chizhou, Anhui, China
  • Taihe County People's Hospital
    Fuyang, Anhui, China
  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui, China
  • Beijing Anzhen Hospital
    Beijing, Beijing, China
  • Beijing Friendship Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • The Second Affiliated Hospital of Fujian Medical University
    Quanzhou, Fujian, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • People's Hospital of Wuhan University
    Wuhan, Hubei, China
  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of Shaoyang University
    Shaoyang, Hunan, China
  • Affiliated Drum Tower Hospital, Medical School of Nanjing University
    Nanjing, Jiangsu, China
  • Jiangyin People's Hospital
    Wuxi, Jiangsu, China
  • Yixing People's Hospital
    Wuxi, Jiangsu, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning, China
  • Shandong Provincial Hospital of Traditional Chinese Medicine
    Jinan, Shandong, China
  • Rizhao People's Hospital
    Rizhao, Shandong, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Dongyang People's Hospital
    Jinhua, Zhejiang, China
  • Jinhua People's Hospital
    Jinhua, Zhejiang, China
  • Lishui People's Hospital
    Lishui, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Sep 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 17, 2025
StartActual
May 10, 2023
Primary completionActual
Sep 23, 2024
CompletionActual
Oct 14, 2024
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06828874
Lead sponsor
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
May 10, 2023
Primary completion
Sep 23, 2024
Completion
Oct 14, 2024
Last update
Feb 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion